| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Molecular Oncology Laboratory, Cancer Research UK, London Research Institute; 2 Center for Cutaneous Biology, Institute for Cell and Molecular Sciences, London, United Kingdom; 3 University of Cambridge, Cancer Research UK, Department of Oncology and the Medical Research Council Cancer Cell Unit, Hutchinson/Medical Research Council Research Centre, Cambridge, United Kingdom; 4 Department of Pathology, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; 5 Free University of Brussels, Laboratory of Molecular Virology, Faculty of Medicine, Brussels, Belgium; and 6 Cytogenetics Unit, Biotechnology Program and 7 Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
Requests for reprints: Jesús Gil, Molecular Oncology Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom. Phone: 44-2072693594; Fax: 44-2072693094; E-mail: jesus.gil{at}cancer.org.uk.
A significant percentage of prostate tumors have amplifications of the c-Myc gene, but the precise role of c-Myc in prostate cancer is not fully understood. Immortalization of human epithelial cells involves both inactivation of the Rb/p16INK4a pathway and telomere maintenance, and it has been recapitulated in culture by expression of the catalytic subunit of telomerase, hTERT, in combination with viral oncoproteins. Here, we show the immortalization of human prostate epithelial cells (HPrEC) by a single genetic event, the expression of the c-Myc oncogene. Myc stabilizes telomere length in HPrEC through up-regulation of hTERT expression and overrides the accumulation of cell cycle inhibitory proteins, such as p16INK4a. Overall, HPrECs expressing c-Myc retain many characteristics of normal cells, such as the induction of a senescence-like growth arrest in response to oncogenic Ras, an intact p53 response, and an absence of gross karyotypic abnormalities. However, HPrECs expressing c-Myc lack a Rb/p16INK4a checkpoint and can be transformed without the need for additional genetic lesions in that pathway. These results give a partial explanation for the physiologic role of c-Myc overexpression in prostate cancer.
Key Words: senescence telomerase prostate transformation Ras
This article has been cited by other articles:
![]() |
J.F. Leal, I. Ferrer, C. Blanco-Aparicio, J. Hernandez-Losa, S. Ramon y Cajal, A. Carnero, and M.E. LLeonart S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis Carcinogenesis, November 1, 2008; 29(11): 2089 - 2095. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mijatovic, N. De Neve, P. Gailly, V. Mathieu, B. Haibe-Kains, G. Bontempi, J. Lapeira, C. Decaestecker, V. Facchini, and R. Kiss Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity Mol. Cancer Ther., May 1, 2008; 7(5): 1285 - 1296. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Neill, W. J. Harrison, M. S. Ikram, T. D.L. Williams, L. S. Bianchi, S. K. Nadendla, J. L. Green, L. Ghali, A.-M. Frischauf, E. A. O'Toole, et al. GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes Carcinogenesis, April 1, 2008; 29(4): 738 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Mallette, M.-F. Gaumont-Leclerc, G. Huot, and G. Ferbeyre Myc Down-regulation as a Mechanism to Activate the Rb Pathway in STAT5A-induced Senescence J. Biol. Chem., November 30, 2007; 282(48): 34938 - 34944. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, G. L. Disbrow, H. Yuan, V. Tomaic, and R. Schlegel Myc and Human Papillomavirus Type 16 E7 Genes Cooperate To Immortalize Human Keratinocytes J. Virol., November 15, 2007; 81(22): 12689 - 12695. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Benanti, M. L. Wang, H. E. Myers, K. L. Robinson, C. Grandori, and D. A. Galloway Epigenetic Down-Regulation of ARF Expression Is a Selection Step in Immortalization of Human Fibroblasts by c-Myc Mol. Cancer Res., November 1, 2007; 5(11): 1181 - 1189. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-B. Song, M.-S. Zeng, W.-T. Liao, L. Zhang, H.-Y. Mo, W.-L. Liu, J.-Y. Shao, Q.-L. Wu, M.-Z. Li, Y.-F. Xia, et al. Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells. Cancer Res., June 15, 2006; 66(12): 6225 - 6232. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kogan, N. Goldfinger, M. Milyavsky, M. Cohen, I. Shats, G. Dobler, H. Klocker, B. Wasylyk, M. Voller, T. Aalders, et al. hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis. Cancer Res., April 1, 2006; 66(7): 3531 - 3540. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Boehm, M. T. Hession, S. E. Bulmer, and W. C. Hahn Transformation of Human and Murine Fibroblasts without Viral Oncoproteins Mol. Cell. Biol., August 1, 2005; 25(15): 6464 - 6474. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |